Lucis said it raised a $20 million Series A led by Singular, with participation from General Catalyst and Y Combinator, to expand its preventive-health platform across Europe and keep developing its biomarker-based product.
Paris-based Lucis said it has raised a $20 million Series A led by Singular, with participation from General Catalyst and Y Combinator, as it looks to expand its preventive-health platform across Europe.
The company announced the round on May 26, 2026. The Next Web and FrenchWeb later published independent coverage confirming the funding and the company’s stated expansion plans.
Lucis said the new capital will support growth into additional European markets and continued product development for its biomarker-based health offering. The startup framed the raise as part of a broader effort to make preventive health more accessible across the region.
Lucis also said the new round brings its total funding to $28 million, following a seed round four months earlier.
The deal adds to a busy funding market for European health startups, but the immediate story is narrower: Lucis now has fresh capital, named backers, and a clear plan to scale its preventive-health product beyond its current footprint.
Revision note
Initial automated publication.